NCT00481143View on ClinicalTrials.gov

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

PHASE4CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

November 30, 2010

Conditions
Myelodysplastic SyndromesTransfusion Dependent Iron Overload
Interventions
DRUG

ICL670/Deferasirox

Trial Locations (1)

12200

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY